Practice Guidelines Recommendations for the Management and Treatment of Dyslipidemia
This review may be edited
Summary
Posted By:	LDS, JJT, JSMW, JKC (UWO)
E-Mail:	disanto@julian.uwo.ca
Posted Date:	June 28, 2000
Title:	Recommendations for the Management and Treatment of Dyslipidemia
Authors:	J. Fodor, J. Frohlich, J. Genest, P. McPherson
Reference:	CMAJ 2000; May 16 162(10): 1441
Link:	Click here for a direct link to the paper. A password may be required for access to fulltext.
Abstract:	Major clinical trials carried out over the past decade have shown a clear benefit of LDL-C reduction in terms of both CAD events and total mortality. A similar reduction in the relative risk of coronary events has been documented in patients with and without clinically evident CAD and in patients with mild or severe dyslipidemia. These advances necessitated a re-evaluation of diagnostic and treatment policies. In 1995 the Working Group on Hypercholesterolemia and Other Dyslipidemias was established at the initiative of Health Canada. Its first report was drafted in October 1996; after review by committee members, modifications were made and the next draft document was released in March 1997. The committee continued to work during the next 2 years, collecting information from Canadian health care providers and the scientific community. An interim report was published in April 1998.17 With the rapid progression of research in this area since then, a writing committee was convened to incorporate the most recent scientific data and expert opinion from various organizations and individuals into this new set of recommendations.
Are the results of the study valid?
Were all important options and outcomes clearly specified?
	Options clearly specified (Table 4, 5, 6). Outcomes less clearly stated (lipid levels and coronary artery disease)
Was an explicit and sensible process used to identify, select, and combine evidence?
	Selection process of the evidence for inclusion not stated. Not a meta-analysis.
Was an explicit and sensible process used to consider the relative value of different outcomes?
	No
Is the guideline likely to account for important recent developments?
	Yes
Has the guideline been subject to peer review and testing?
	Peer Review - Yes Testing - Not mentioned
What were the results?
Are practical, clinically important, recommendations made?
	Yes (healthy diet, regular physical activity, ideal body weight, moderate alcohol, stop smoking, lipid lowering meds)
How strong are the recommendations?
	Levels of evidence not stated.
What is the impact of uncertainty associated with the evidence and values used in the guidelines?
	Uncertainty (statistics) not stated.
Will the results help me in caring for my patients?
Is the primary objective of the guideline consistent with your objective?
	Yes
Are the recommendations applicable to your patients?
	Very applicable.
What other people had to say about: Recommendations for the Management and Treatment of Dyslipidemia Add Your Comment
[ Back ] Any questions or comments please contact Gordon S. Doig Implemented and designed by John Soer and Gordon Doig Page last modified on Friday, August 10, 2001 www.EvidenceBased.net
	THIS IS A SPACE MESSAGE. THIS IS STILL THE BEST METHOD TO SPACE A TABLE FOR NETSCAPE AND INTERNET EXPLORER. IF YOU SEE THIS MESSAGE CONTACT WEBADMIN@EvidenceBased.net